Thermo Fisher Scientific Inc. $TMO Shares Purchased by Axxcess Wealth Management LLC

Key Points

• Axxcess Wealth Management LLC has increased its holdings in Thermo Fisher Scientific Inc. by 4.5%, now owning 24,817 shares valued at approximately $10 million.
• Institutional investors currently hold 89.23% of Thermo Fisher's stock, indicating strong institutional interest in the company.
• Analysts have set varying price targets for Thermo Fisher Scientific, with a consensus target price of $589.10 and a general rating of "Moderate Buy."

Axxcess Wealth Management LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,817 shares of the medical research company's stock after buying an additional 1,069 shares during the quarter. Axxcess Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $10,063,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. DiNuzzo Private Wealth Inc. raised its position in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after purchasing an additional 45 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TMO. UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Evercore ISI increased their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $589.10.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $524.80 on Tuesday. The stock has a fifty day moving average price of $489.83 and a two-hundred day moving average price of $447.66. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $198.17 billion, a P/E ratio of 30.35, a PEG ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.